

Author's Proof

Before checking your proof, **please read the instructions below**

- Carefully read the entire proof and mark all corrections in the appropriate place, using the Adobe Reader commenting tools (**Adobe Help**).
- Provide your corrections in a single PDF file or post your comments in the Production Forum making sure to reference the relevant query/line number. Upload or post all your corrections directly in the Production Forum to avoid any comments being missed.
- We do not accept corrections in the form of edited manuscripts nor via email.
- Do not provide scanned or handwritten corrections.
- Before you submit your corrections, please make sure that you have checked your proof carefully as once you approve it, you won't be able to make any further corrections.
- To ensure the timely publication of your article, please submit the corrections within 48 hours. After submitting, do not email or query asking for confirmation of receipt.

Do you need help? Visit our **Production Help Center** for more information. If you can't find an answer to your question, contact your Production team directly by posting in the Production Forum.

Quick checklist

- ☐ **Author names** - Complete, accurate and consistent with your previous publications
- ☐ **Affiliations** - Complete and accurate. Follow this style when applicable: Department, Institute, University, City, Country
- ☐ **Tables** - Make sure our formatting style did not change the meaning/alignment of your Tables.
- ☐ **Figures** - Make sure we are using the latest versions.
- ☐ **Funding and Acknowledgments** - List all relevant funders and acknowledgments.
- ☐ **Conflict of Interest** - Ensure any relevant conflicts are declared.
- ☐ **Supplementary files** - Ensure the latest files are published and that no line numbers and tracked changes are visible. Also, the supplementary files should be cited in the article body text.
- ☐ **Queries** - Reply to all typesetters queries below
- ☐ **Content** - Read all content carefully and ensure any necessary corrections are made.

Author queries form

Query no.	Details required	Authors response
Q1	Confirm whether the article title is correct.	
Q2	The emphases (highlights) from revisions were removed throughout the article. Confirm that this change is fine.	
Q3	The citation and surnames of all of the authors have been highlighted. Check that they are correct and consistent with your previous publications, and correct them if needed. Please note that this may affect the indexing of your article in repositories such as PubMed. If adding/removing authors, or changing the order of this list, please provide us with a signed Authorship Change form	
Q4	Confirm that the email address in your correspondence section is accurate. Any changes to corresponding authors requires individual confirmation from all original and added/removed corresponding authors.	

Q5	There is a discrepancy between the styling of the author names in the submission system and the manuscript. We have used "Haitao Lv" instead of "Lv Haitao ". Please confirm that it is correct.	
Q6	Confirm that all author affiliations are correctly listed. Per our style guidelines, affiliations are listed sequentially and follow author order. Requests for non-sequential affiliation listing will not be fulfilled. Note that affiliations should reflect those at the time during which the work was undertaken. If adding new affiliations, specify if these should be listed as a present address instead of a regular affiliation.	
Q7	Confirm that the keywords are correct, and keep them to a maximum of eight and a minimum of five. (Note: a keyword can be made up of one or more words.)	
Q8	Check if the section headers (i.e., section leveling) have been correctly captured.	
Q9	If you decide to use previously published and/or copyrighted figures in your article, please keep in mind that it is your responsibility as the author to obtain the appropriate permissions and licenses to reproduce them, and to follow any citation instructions requested by third-party rights holders. If obtaining the reproduction rights involves the payment of a fee, these charges are to be paid by the authors.	
Q10	Check that all equations and special characters are displayed correctly.	
Q11	If the following authors would like their LOOP profile to be linked to the final published version, ensure that they register with Frontiers at the provided link, and provide us with the URLs to their profile(s). Non-registered authors and authors with profiles set to "Private" will have the default profile image displayed. Note that we will not be able to add profile links after publication. "Jinfeng Dong" "Jiaqi Jiang" "Fang Yang" "Shuhui Wang" "Lijun Meng" "Wenyu Zhuo" "Daoping Yang" "Qiaobin Chen" "Guoping You"	
Q12	Ensure that all the figures, tables, and captions are correct, and that all figures are of the highest quality/resolution. If necessary, you may upload improved figures to the Production Forum. Please note that figures and tables must be cited sequentially, per the author guidelines	
Q13	Ensure all grant numbers and funding information are included and accurate (after publication it is not possible to change this information). All funders should be credited, and all grant numbers should be correctly included in this section.	
Q14	Confirm if the text included in the Conflict of Interest statement is correct. Please do not suggest edits to the wording of the final sentence, as this is standard for Frontiers' journal style.	

Q15	Confirm that the Data Availability statement is accurate. Note that this statement may have been amended to adhere to our Publication Ethics guidelines.	
Q16	If your article requires an Ethics statement, please confirm that the statement in this proof is correct. If this is not the latest version, please provide a revised Ethics statement. If your article contains identifiable human images, please check our Policies and Publication Ethics here .	
Q17	<p>Ensure that any supplementary material is correctly published at this link: https://www.frontiersin.org/articles/10.3389/fimmu.2022.1090056/full#supplementary-material</p> <p>If the link does not work, you can check the file(s) directly in the production forum; the published supplementary files appear in green. Please make sure all Supplementary files are cited. Please also provide captions for these files, if relevant.</p> <p>If you have any corrections, please provide new files and republish them in the forum.</p> <p>Frontiers will deposit ALL supplementary files to FigShare and they will receive a DOI.</p> <p>Notify us of any previously deposited material.</p> <p>If the Supplementary Material files contain identifiable or copyright images, please keep in mind that it is your responsibility, as the author, to ensure you have permission to use the images in the article. Please check this link for information on author responsibilities and the publication images.</p>	
Q18	Confirm that the details in the "Author Contributions" section are correct. We have added the sentence "All authors contributed to the article and approved the submitted version."	
Q19	<p>Please confirm if this should be moved to the Funding:</p> <p>"HH received support from the China Scholarship Council for 1 year study at the Max-Planck Institute for Heart and Lung Research. LG was supported by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation), EXC 2026, Cardio-Pulmonary Institute (CPI), Project ID 390649896."</p>	
Q20	Provide the page range for the following references, if applicable. 9, 21, 40.	
Q21	Provide the journal title, volume number and page range for the following reference, if applicable. 12.	
Q22	Provide the volume number and page range for the following reference, if applicable. 29.	
Q23	Provide the journal title and volume number for the following reference, if applicable. 42.	
Q24	Please provide the doi for "12; 22", if applicable.	
Q25	Note that Affiliations 3 to 6 were interchanged since their affiliations need to be listed in sequential order, per our style.	
Q26	The image used in Figures 1 and 7 does not have *** symbol; however, the description were present in the caption.	
Q27	The image used in Figures 3 and 4 does not have * symbol; however, the description were present in the caption.	

Q28	The image used in Figures 6 and 7 does not have **** symbol; however, the description were present in the caption.	
------------	--	--



OPEN ACCESS

EDITED BY
Chit Laa Poh,
Sunway University, Malaysia

REVIEWED BY
Kasturi Mahadik,
Centre for Cellular & Molecular
Biology (CCMB), India
Liang Bai,
Xi'an Jiaotong University, China

Q4

*CORRESPONDENCE

Haitao Lv
✉ lvhaitao@suda.edu.cn
Lei Gu
✉ Lei.Gu@mpi-bn.mpg.de

[†]These authors have contributed
equally to this work

SPECIALTY SECTION

This article was submitted to
Inflammation,
a section of the journal
Frontiers in Immunology

RECEIVED 04 November 2022

ACCEPTED 19 December 2022

PUBLISHED xx xx 2023

CITATION

Huang H, Dong J, Jiang J, Yang F,
Zheng Y, Wang S, Wang N, Ma J,
Hou M, Ding Y, Meng L, Zhuo W,
Yang D, Qian W, Chen Q, You G,
Qian G, Gu L and Lv H (2023) The role
of FOXO4/NFAT2 signaling pathway in
dysfunction of human coronary
endothelial cells and inflammatory
infiltration of vasculitis in Kawasaki
disease.
Front. Immunol. 13:1090056.
doi: 10.3389/fimmu.2022.1090056

COPYRIGHT

© 2023 Huang, Dong, Jiang, Yang,
Zheng, Wang, Wang, Ma, Hou, Ding,
Meng, Zhuo, Yang, Qian, Chen, You,
Qian, Gu and Lv. This is an open-access
article distributed under the terms of
the [Creative Commons Attribution
License \(CC BY\)](#). The use, distribution
or reproduction in other forums is
permitted, provided the original
author(s) and the copyright owner(s)
are credited and that the original
publication in this journal is cited, in
accordance with accepted academic
practice. No use, distribution or
reproduction is permitted which does
not comply with these terms.

The role of FOXO4/NFAT2 signaling pathway in dysfunction of human coronary endothelial cells and inflammatory infiltration of vasculitis in Kawasaki disease

Q1 Q2

Hongbiao Huang^{1,2,3†}, Jinfeng Dong^{4†}, Jiaqi Jiang^{1†},
Fang Yang^{2†}, Yiming Zheng¹, Shuhui Wang¹, Nana Wang¹,
Jin Ma¹, Miao Hou¹, Yueyue Ding¹, Lijun Meng⁵,
Wenyu Zhuo¹, Daoping Yang¹, Weiguo Qian¹, Qiaobin Chen²,
Guoping You⁶, Guanghui Qian¹, Lei Gu^{3*} and Haitao Lv^{1*}

Q3 Q11

Q5

Q25

¹Department of Pediatrics, Institute of Pediatric Research, Children's Hospital of Soochow University, Suzhou, Jiangsu, China, ²Department of Pediatrics, Fujian Provincial Hospital, Fujian Provincial Clinical College of Fujian Medical University, Fuzhou, Fujian, China, ³Epigenetics Laboratory, Max Planck Institute for Heart and Lung Research, Bad Nauheim, Germany,

⁴Department of Hematology, the First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China, ⁵Department of Hematology, Children's Hospital of Soochow University, Suzhou, China, ⁶Department of Emergency, Fujian Provincial Hospital, Fujian Provincial Clinical College of Fujian Medical University, Fuzhou, Fujian, China

Q6

Aims: The Ca²⁺/NFAT (Nuclear factor of activated T cells) signaling pathway activation is implicated in the pathogenesis of Kawasaki disease (KD); however, we lack detailed information regarding the regulatory network involved in the human coronary endothelial cell dysfunction and cardiovascular lesion development. Herein, we aimed to use mouse and endothelial cell models of KD vasculitis *in vivo* and *in vitro* to characterize the regulatory network of NFAT pathway in KD.

Methods and Results: Among the NFAT gene family, *NFAT2* showed the strongest transcriptional activity in peripheral blood mononuclear cells (PBMCs) from patients with KD. Then, *NFAT2* overexpression and knockdown experiments in Human coronary artery endothelial cells (HCAECs) indicated that *NFAT2* overexpression disrupted endothelial cell homeostasis by regulation of adherens junctions, whereas its knockdown protected HCAECs from such dysfunction. Combined analysis using RNA-sequencing and transcription factor (TF) binding site analysis in the *NFAT2* promoter region predicted regulation by Forkhead box O4 (FOXO4). Western blotting, chromatin immunoprecipitation, and luciferase assays validated that *FOXO4* binds to the promoter and transcriptionally represses *NFAT2*. Moreover, *Foxo4* knockout increased the extent of inflamed vascular tissues in a mouse model of

KD vasculitis. Functional experiments showed that inhibition NFAT2 relieved *Foxo4* knockout exaggerated vasculitis *in vivo*.

Conclusions: Our findings revealed the FOXO4/NFAT2 axis as a vital pathway in the progression of KD that is associated with endothelial cell homeostasis and cardiovascular inflammation development.

KEYWORDS

Kawasaki disease, FOXO4, Ca⁺/NFAT pathway, transcription factor, vasculitis

Q7

Q8 1 Introduction

Q10

Kawasaki disease (KD) is an acute vasculitis that is self-limiting and affects children. In developed countries, KD represents the most common cause of childhood acquired heart disease (1). Serious complications include coronary artery disease, which is closely related to the incidence of cardiovascular disease, especially coronary heart disease in adulthood (2), thus, a deeper mechanistic understanding of KD is required.

The incidence of KD differs among ethnicities, thus research linking genetic background to disease susceptibility has led to improved clinical trials (3). The only signaling pathway mentioned in the Genetics section of 2017 AHA guidelines as being related to clinical treatment is the Nuclear factor of activated T cells (NFAT) pathway (3). NFAT signaling affects immune cells and endothelial cells. The reasons for these phenotypes are the expression of downstream cytokines and adhesion proteins (4, 5). Although our understanding of the relationship between NFAT signaling and KD has developed in recent decades, the detailed mechanisms of NFAT activation in KD remain unknown.

NFAT was first identified as a member of an inducible nuclear protein complex involving interleukin-2 (IL-2) in T cells (6). The NFAT transcription factor family includes five members. NFAT1 (NFATc2 or NFATp) was first identified in 1993 (7). Phosphatase calcineurin regulates NFAT2 (NFATc1 or NFATc) (8), and NFAT3~5 were also identified recently (9). Research showed that NFAT acts as a transcriptional activator in the nucleus during the development of KD. Recent research showed that NFAT signaling activation disturbs the homeostasis of human coronary artery endothelial cells (HCAECs) (4). However, the function of the NFAT pathway in HCAECs, particularly in causing KD-related vasculitis, has not been determined.

In the present study, to identify the NFAT family member with the strongest transcriptional activation in KD, their relative expression in peripheral blood mononuclear cells (PBMCs) from

patients with KD and dual luciferase experiments were carried out. NFAT2 had the strongest transcriptional activation in the NFAT family, and overexpression and knockdown of NFAT2 in HCAECs demonstrated its important role in HCAEC homeostasis *in vitro*. We also predicted that the upstream transcription factor of NFAT2 is Forkhead box O4 (FOXO4), which binds to the NFAT2 promoter region, as verified using chromatin immunoprecipitation-quantitative polymerase chain reaction (ChIP-qPCR).

Next, we developed a *Candida albicans* water-soluble fraction (CAWS)-induced KD vasculitis mouse model, allowing us to detect NFAT2 and FOXO4 expression in PBMCs and heart tissues. The specific NFAT inhibitory peptide (11arginine (R)-VIVIT) has been used to observe the pathological changes after suppressing NFAT signaling (10). Moreover, by generating *Foxo4* knockout mice combined with (11R)-VIVIT, we demonstrated that FOXO4 is a negative regulator in CAWS-induced KD vasculitis and NFAT2 is a positive regulator. Blocking NFAT signaling reduced the severity of KD vasculitis-associated vascular inflammation in wild-type (WT) mice and *Foxo4* knockout mice. Therefore, we identified that NFAT2 promotes KD and FOXO4 transcriptionally represses NFAT2 during the progression of KD vasculitis.

2 Methods

2.1 Sampling of human blood

The study was carried out following the tenets of the Declaration of Helsinki and the Ethics Committee of Soochow University Affiliated Children's Hospital approved the study (Suzhou, China; approval no. 2020CS075). The Ethics Committee informed all the participants and their parents about the study details, who then provided written informed consent. Details about Sampling human blood are provided in the [Supplemental material](#).

2.2 Genetically engineered mice

Details about genetically engineered mice are provided in the [Supplemental material](#).

2.3 Preparation of CAWS

The CAWS was prepared from *Candida albicans* strain NBRC1385 using previously described methods (11–13) and the details are provided in the [Supplemental material](#).

2.4 CAWS-induced vasculitis in mouse model

All animal experiments were carried out following the Guide for the Care and Use of Laboratory Animals of the China National Institutes of Health, and the Animal Care and Use Committee of Soochow University approved the experiments (approval number: SUDA20220906A01). Details about the preparation of the genetically engineered mice are provided in the [Supplemental material](#).

2.5 Histology and immunohistochemical staining

The sections were stained using hematoxylin and eosin (HE) and elastic van Gieson (EVG) staining as described previously (14). The severity of inflammatory infiltration was evaluated using heart vessel inflammation scores (15). The immunohistochemical quantification used modified H-scores (16) and details are provided in the [Supplemental material](#).

2.6 Immunofluorescence staining

More detailed descriptions about the experiments are provided in the [Supplemental material](#).

2.7 Cell culture

Detailed descriptions of the cell culture conditions for HCAECs cells are provided in the [Supplemental Information](#).

2.8 FOXO4 knockdown, FOXO4 overexpression, NFAT2 knockdown and NFAT2 overexpression in HCAEC cells

We packaged the lentiviruses according to a previously described method (17) and the details are provided in the [Supplemental material](#).

2.9 Stimulation of cultured HCAECs with tumor necrosis factor- α

Details about these experiments are provided in the [Supplemental material](#).

2.10 RNA extraction and quantitative real-time reverse transcription PCR

Experimental and primer details are provided in the [Supplemental material](#). The $2^{-\Delta\Delta Ct}$ method (18) was used to analyze the qRT-PCR data.

2.11 Western blotting

The details about the western blotting analysis are provided in [Supplemental material](#).

2.12 Luciferase assay

The details about the Luciferase assay are provided in the [Supplemental material](#).

2.13 Chromatin immunoprecipitation assay

The ChIP assay was carried out according to a previously described method (19) and is detailed in the [Supplemental material](#).

2.14 RNA sequencing

The details about the RNA-seq experiment are provided in the [Supplemental material](#).

2.15 Cell proliferation assays

The details about cell proliferation assays are provided in the [Supplemental material](#).

2.16 Statistical analysis

The details about the statistical analysis are provided in the [Supplemental material](#).

3 Results

3.1 NFAT2 was significantly elevated in PBMCs from patients with KD and in the TNF α -stimulated HCAEC model

qRT-PCR analysis of PBMCs revealed that compared with other members of the NFAT family, *NFAT2* mRNA levels were significantly upregulated in patients diagnosed with KD compared with that in the healthy controls ([Figure 1A](#)). The luciferase reporter assays showed that *NFAT2* had the strongest

transcriptional activity among the NFAT family ([Figure 1B](#)). To further determine the critical roles of NFAT2 in KD, 40 ng/ml TNF α was used to stimulate HCAECs to mimic vasculitis *in vitro*. The dose of TNF α was determined by the expression of NFAT2 after HCAECs were stimulated by different doses ([Supplementary Figure 1A](#)). Over 0–8 hours of stimulation, *NFAT2* mRNA showed the highest upregulation compared with other members of the NFAT family ([Figure 1C](#)). Similarly, the RNA-seq results at different timepoints also showed that *NFAT2* expression increased most significantly compared with the TNF α stimulation group at zero hour ([Supplementary Figure 1B](#)). These findings clearly demonstrated upregulated *NFAT2* mRNA expression in patients and in vasculitis *in vitro*, suggesting that NFAT2 has an important function in the development of KD.

3.2 NFAT2 disrupted the homeostasis of endothelial cells by regulating adherens junctions

To investigate the function of NFAT2 in HCAECs, *NFAT2* overexpression (OE) and knockdown (KnD) lentiviruses were transfected into HCAECs and empty lentiviral vectors for




FIGURE 1

Levels of *NFAT2* mRNA increase during Kawasaki Disease progression. (A) qRT-PCR results for peripheral blood mononuclear cells (PBMCs) in blood samples from patients with Kawasaki Disease ($n = 12$) and healthy controls ($n = 15$). (B) 293T cells were transfected with control plasmid or *NFAT1*~*NFAT5*, together with NFAT-Luc and Renilla plasmids respectively. The cells were harvested 72 hours after transfection. The relative activity of NFAT-driven firefly luciferase activity was normalized to that of Renilla luciferase activity (Firefly-luc/Renilla-luc). (C) qRT-PCR results of NFAT family members in HCAEC that were stimulated by TNF α (40 ng/ml) at different timepoints ($n = 3$). Data are presented as the mean \pm SEM. Quantitative data were analyzed using the Kruskal–Wallis test (A) and one-way ANOVA (C), * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, **** $P < 0.0001$. CON, control group; KD, Kawasaki Disease; NFAT, nuclear factor of activated T cells; HCAEC, Human coronary artery endothelial cells; ANOVA, analysis of variance.

Q9
Q12
Q26

overexpression (OE-CON) and knockdown (KnD-CON) were employed as the appropriate controls. *NFAT2* overexpression and knockdown in HCAECs were verified using western blotting and qRT-PCR (Figures 2A–D).

Next, we used RNA-Seq to investigate the mechanism of *NFAT2* in HCAECs. Differentially expressed genes (DEGs) in the RNA-Seq data were identified using mRNA clustering and map plotting, with criteria of an absolute value \log_2 FoldChange




FIGURE 2

NFAT2 disrupted endothelial cell homeostasis. (A, B) At 7 days after transfection of *NFAT2* overexpressing lentiviruses (OE-NFAT2) and their corresponding control (OE-CON), (A) *NFAT2* protein levels were assayed using western blotting, with a loading control comprising GAPDH, and (B) *NFAT2* mRNA expression was assessed using qRT-PCR ($n = 3$). (C, D) At 7 days after transfection of lentiviruses for the knockdown *NFAT2* (sh1~sh3) and its corresponding controls (KnD-CON), (C) western blotting was used to assess *NFAT2* protein levels, with a loading control comprising GAPDH, and (D) *NFAT2* mRNA expression was assessed using qRT-PCR ($n = 3$). (E, F) Volcano plot showing differentially expressed genes (DEGs) in response to *NFAT2* overexpression (E) or *NFAT2* knockdown (F). Red dots represent upregulated genes; and blue dots represent downregulated genes. Gene Ontology (GO) functional enrichment analysis of DEGs related to *NFAT2* overexpression (G) and *NFAT2* knockdown (H). (I) HCAECs transfected with *NFAT2* overexpressing lentiviruses (OE-NFAT2) and their corresponding control (OE-CON) were stimulated with/without TNF α (40 ng/ml) for 4 hours. CDH5 and *NFAT2* protein levels were analyzed. β -Actin served as a loading control. (J) HCAECs transfected with *NFAT2* knockdown lentiviruses (shNFAT2) and their corresponding control (KnD-CON) were stimulated with/without TNF α (40 ng/ml) for 4 hours. CDH5 and *NFAT2* protein levels were analyzed as described. β -Actin served as a loading control. (K–M) The expression of CDH5 was detected by immunofluorescence. *NFAT2* overexpression (K) and knockdown (L) vectors and their corresponding controls were transfected into HCAECs, respectively. After 7 days, cells were stimulated with/without TNF α (40 ng/ml) for 4 hours. The cells were immunostained with rabbit anti-CDH5, followed by staining with 594 goat anti-rabbit IgG (red). Cell nuclei were stained with DAPI (blue). The fluorescent images were captured (K). The immunofluorescence area per cell in the different groups is shown (M) ($n = 3$). (N) HCAECs were transfected with *NFAT2* overexpression and knockdown vectors and their corresponding controls. After 5 days and 7 days, the proliferation of HCAECs was detected using a CCK8 assay ($n = 7$). Data are presented as the mean \pm SEM. Quantitative data were analyzed using an unpaired t test (two-tailed) (B, D) and one-way ANOVA (M, N), * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, **** $P < 0.0001$.

> 0 and an adjusted $p < 0.05$. Overexpression of *NFAT2* resulted in the upregulation of 2100 genes and the downregulation of 2541 genes (Figure 2E). Knockdown of *NFAT2* resulted in the upregulation of 808 genes and the downregulation of 846 genes in HCAECs (Figure 2F). Gene ontology (GO) analysis was then used to functionally annotate the DEGs. The GO results indicated that the genes regulated by *NFAT2* were involved in the regulation of adherens junctions, such as cell adhesion molecule binding and cell-substrate junction (Figures 2G, H).

To confirm the GO results, we chose the classical molecule Cadherin 5 (CDH5) to carry out an adherens junction experiment in HCAECs (20, 21). *NFAT2* negatively regulated CDH5 expression in both the overexpression and knockdown group. The protein level of CDH5 decreased after $\text{TNF}\alpha$ stimulation, regardless of whether *NFAT2* was overexpressed or not (Figures 2I, J). Consistently, immunofluorescence staining for CDH5 showed that overexpression of *NFAT2* notably disrupted CDH5 formation. Conversely, knockdown of *NFAT2* promoted the formation of CDH5. Regardless of the expression level of *NFAT2*, CDH5 levels were decreased in $\text{TNF}\alpha$ -stimulated cells compared with that in $\text{TNF}\alpha$ non-treated HCAECs (Figures 2K–M).

We also evaluated HCAEC proliferation using Counting Kit-8 (CCK8) assays (4). The results showed that the proliferation of HCAECs in the OE-*NFAT2* group at 5 and 7 days was significantly lower than that in the OE-CON group. In the KnD-*NFAT2* group, HCAEC proliferation was not statistically significant at 5 days, but was significantly higher than that in the KnD-CON group at 7 days (Figure 2N). Collectively, the data indicated that *NFAT2* has a vital function in the homeostasis of HCAECs.

3.3 FOXO4 negatively regulates NFAT2 in HCAECs

Next, we investigated the regulation of *NFAT2* *in vitro*. We identified genes with variable expression in the *in vitro* vasculitis model that could interact with the *NFAT2* promoter region as possible *NFAT2* regulators. The RNA-seq analysis was carried out between HCAECs stimulated with $\text{TNF}\alpha$ for 4 h and unstimulated cells to identify DEGs (Figure 3A). The LASAGNA-Search 2.0 database was used to predict proteins that can interact with the promoter region of *NFAT2* (22) (Supplementary Figure 1C). Among the DEGs that were altered in the *in vitro* vasculitis model, four encoded proteins that might bind to the *NFAT2* promoter (Figures 3B, C). Among them, FOXO4 had highest prediction score. In addition, during $\text{TNF}\alpha$ stimulation of HCAECs for different times, FOXO4 mRNA expression decreased significantly after 4 h (Supplementary Figures 1B, D).

To observe the expression of FOXO4 in immune cells, we detected the mRNA expression of FOXO4 in PBMCs from the

healthy control group and patients with KD. Compared with that in the control group, the KD group had lower FOXO4 expression in PBMCs (Figure 3D).

To identify the relationship between FOXO4 and *NFAT2*, several experiments were carried out *in vitro*. First, increasing amounts of the FOXO4 overexpression plasmid were transfected into 293T cells. The immunoblotting results showed that FOXO4 overexpression decreased the endogenous *NFAT2* protein level in 293T cells. The increased amounts of transfected FOXO4 led to a dose-dependent decrease in the levels of *NFAT2* (Figure 3E). Consistent with protein level, *NFAT2* mRNA expression decreased gradually in cells overexpressing FOXO4 (Figures 3F, G), suggesting that FOXO4 regulates *NFAT2* at the mRNA level. We then showed that FOXO4 overexpression decreased the protein level of *NFAT2*, whereas FOXO4 knockdown increased it in HCAECs (Figures 3H, I). It is very difficult to transfect multiple plasmids into HCAECs at the same time; therefore, we used 293T cells for the luciferase assays, similar to previous research (23). Luciferase reporter assays showed that FOXO4 overexpression inhibited the activation of the *NFAT2* reporter (Figure 3J), suggesting that FOXO4 regulates the transcription of *NFAT2*.

To further determine whether FOXO4 directly regulates *NFAT2* in HCAECs, we carried out a ChIP assay in HCAECs transfected with FLAG-tagged FOXO4 lentivirus to identify the binding regions. Primers were designed to amplify various genomic fragments upstream of the transcription start site of *NFAT2*. Real-time PCR assays of the immunoprecipitated DNA revealed that the P3–5 (–2331/–1049 bp) fragments had the highest enrichment (Figure 3K). Other fragments were not enriched compared with the immunoglobulin G control (Figure 3K). According to the luciferase activities, FOXO4 repressed both the basal *NFAT2* transcription and that driven by the –2300/–1000 fragment in a dose-dependent manner (Figure 3L). Thus, these results identified FOXO4 as a transcriptional repressor of *NFAT2* that physically binds to the –2300/–1000 region of its promoter.

3.4 FOXO4 stabilized the homeostasis of endothelial cells

Next, we investigated if FOXO4 has opposite functions to those of *NFAT2*. FOXO4 overexpression (OE) and knockdown (KnD) lentiviruses were transfected into HCAECs. The protein level of CDH5 decreased after $\text{TNF}\alpha$ stimulation regardless of FOXO4 overexpression (Figures 4A, B). Immunofluorescence staining for CDH5 indicated that FOXO4 overexpression promoted CDH5 formation at intercellular borders, which was consistent with the western blotting results. $\text{TNF}\alpha$ -stimulated HCAECs showed lower CDH5 levels than $\text{TNF}\alpha$ non-treated HCAECs (Figures 4C–E).




FIGURE 3

FOXO4 negatively regulates NFAT2 by inhibiting its transcription binding to its promoter *in vitro*. (A) Volcano plot map of differentially expressed genes (DEGs) in HCAECs stimulated by TNF α (40ng/ml) for 4 hours. Red dots, upregulated genes; blue dots, downregulated genes. (B) Venn diagram displaying the overlapping genes between the DEGs in (B) and target genes predicted to have NFAT2 binding sites in their promoter or transcription start site according to the LASAGNA-Search 2.0 database. (C) Detailed information for the four overlapping genes. (D) FOXO4 mRNA expression in peripheral blood mononuclear cells (PBMCs) in blood samples from patients with Kawasaki Disease (n = 11) and healthy controls (n = 11). (E) Immunoblotting analysis of NFAT2 levels in 293T cells transfected with the empty vector or an increasing amount of FOXO4 plasmid. (F, G) qRT-PCR results of 293T cells transfected with empty vector or an increasing amount of FOXO4 plasmid. mRNA expression of FOXO4 (F) and NFAT2 (G). (H-I) HCAECs were transfected with FOXO4 overexpression (OE-FOXO4) (H) and knockdown (shFOXO4) (I) lentiviruses and their corresponding controls for 7 days. FOXO4 and NFAT2 levels were analyzed. The loading control was β -Actin. (J) 293T cells were transfected with the control plasmid or increasing amounts of the FOXO4 plasmid, together with NFAT_Luc and Renilla plasmids, respectively. The cells were harvested at 72 hours after transfection. The relative NFAT-driven firefly luciferase activity was normalized to that of Renilla luciferase (Firefly-luc/Renilla-luc). (K) HCAECs transfected with FOXO4 overexpressing lentiviruses were subjected to a ChIP assay. Real-time PCR with the indicated primers was used to assess the abundance of gene fragments in the input and immunoprecipitates. The upper image shows the NFAT2 gene expression and the lower image shows the locations of primers for the ChIP assay. (L) The Firefly-luc/Renilla-luc in 293T cells transfected with the indicated plasmids. The location of the transcription start site in NFAT2 was set as 0. Therefore, -2300 and -1000 indicate the upstream 1000~2300 bp fragments, respectively. IgG, immunoglobulin (G). Data are presented as the mean \pm SEM. Quantitative data were analyzed using the Mann-Whitney test (two-tailed) (D) and one-way ANOVA (F, G, J), *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.

The proliferation of HCAECs in the OE-FOXO4 group was significantly higher than that in the OE-CON group and proliferation in the KnD-FOXO4 group was significantly lower than that in the KnD-CON group at 7 days (Figure 4F). These

data strongly suggested that FOXO4 has the opposite function to NFAT2 in maintaining endothelial cell homeostasis.




FIGURE 4

FOXO4 stabilized endothelial cell homeostasis *in vitro*. (A) HCAECs transfected with lentiviruses to knockdown FOXO4 (shFOXO4) and their corresponding controls (KnD-CON) were stimulated with/without TNFα (40 ng/ml) for 4 hours. CDH5 and FOXO4 levels were analyzed. The loading control was β-Actin. (B) HCAECs transfected with lentiviruses overexpressing FOXO4 (OE-FOXO4) and their corresponding controls (OE-CON) were stimulated with/without TNFα (40 ng/ml) for 4 hours. CDH5 and NFAT2 protein level were analyzed. The loading control was β-Actin. (C-E) CDH5 expression was detected using immunofluorescence. FOXO4 overexpression (C) and knockdown (D) vectors and their corresponding controls were transfected into HCAECs, respectively. After 7 days, cells were stimulated with/without TNFα (40 ng/ml) for 4 hours. The cells were then immunostained with rabbit anti-CDH5, followed by staining with 594 goat anti-rabbit IgG (red). Cell nuclei were stained with DAPI (blue) and the fluorescent images were captured. The immunofluorescence area per cell in the different groups (n = 3) (E). (F) FOXO4 overexpression and knockdown vectors and their corresponding controls were transfected into HCAECs, respectively. After 5 days and 7 days, CCK8 assays were used to detect HCAEC proliferation (n = 7). Data are presented as the mean ± SEM. Quantitative data were analyzed using one-way ANOVA (E, F). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.

3.5 The expression of NFAT2 is upregulated in CAWS-induced vasculitis

We further investigated the *in vivo* expression of NFAT2 and FOXO4. CAWS-induced vasculitis is widely used to study KD because the coronary artery lesions induced by CAWS are similar those of human KD (24). We tested different timepoints after CAWS injection to identify the most appropriate timepoint (Figure 5A). The weight of mice decreased slightly after the injection of CAWS, with the most obvious difference between the weight of the CAWS and control groups being observed at 14 days after CAWS injection (Figure 5B, Supplementary Figure 2D). HE and EVG staining

indicated that perivascular inflammation began 14 days after CAWS injection, and the inflammatory infiltration was more obvious and the fibrous tissue damage was more serious at 28 days after CAWS injection (Figures 5C-E, Supplementary Figure 2A-C).

In PBMCs of CAWS injected mice, *Nfat2* expression increased significantly at 14 days after CAWS injection (Figure 5F) and *Foxo4* expression decreased (Figure 5G). Interestingly, the expression of *Foxo4* increased at 28 days (Figure 5G and Supplementary Figure 2F-H). In the heart tissue of the CAWS injected mice, the protein level of NFAT2 showed a similar phenomenon (Figure 5H). Therefore, we used 14 days after CAWS injection as the timepoint in the vasculitis




FIGURE 5

NFAT2 expression levels are upregulated during the progression of CAWS-induced vasculitis. (A) The protocol for constructing the CAWS-induced mouse model. (B) The change of weight during ($n = 5$) and after ($n = 5$) PBS/CAWS injection in mice. (C, D) At different timepoints the mouse were sacrificed, heart tissues were harvested, made into sections, and subjected to hematoxylin and eosin (HE) staining (C) and elastic van Gieson (EVG) staining (D). Scale bars, 200 μ m (50 \times) (Large) and 10 μ m (200 \times) (Small). (E) Scores of heart vessel inflammation for WT mice injected with CAWS ($n = 5$). (F–H) NFAT expression was significantly upregulated at 14–28 days after CAWS injection, at the mRNA level in PBMCs ($n = 3$) (F) and at the protein level in heart tissues (H), especially after 14 days. (G) The mRNA expression of *Foxo4* was almost opposite to that of *Nfat2* in PBMCs ($n = 3$). (I, J) NFAT expression was upregulated and that of FOXO4 was downregulated in heart tissues at 14 days after CAWS injection at both protein ($n = 3$) (I) and mRNA (J) levels. (K) Immunofluorescence imaging of FOXO4 (green) and NFAT2 (red) in heart sections from PBS/CAWS-injected 14 days WT group mice. Scale bars, 200 μ m (50 \times) and 10 μ m (200 \times). All images show DAPI staining of nuclei. (L) Mean fluorescence intensity of FOXO4 and NFAT2 in heart sections from PBS/CAWS-injected 14 days WT group mice. (M–O) Immunohistochemical staining for CDH5 in heart sections from PBS-injected (M) and CAWS-injected (N) WT group mice. CDH5 protein levels quantified using the H-score (O) ($n = 3$). Data are presented as the mean \pm SEM. Quantitative data were analyzed using unpaired t tests (two-tailed) (B, F, G, J, L, O) and the Mann–Whitney test (two-tailed) (E) * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, **** $P < 0.0001$.

model for follow-up studies. FOXO4 was downregulated at both the mRNA and protein level at 14 days after CAWS injection (Figure 5I, J). The LASAGNA-Search 2.0 database also predicted target proteins that bind the promoter of *Nfat2* in the mouse, including FOXO4 ((Supplementary Figure 2E)).

Next, we sought to determine whether the increase of NFAT2 was associated with the inflamed region from CAWS-injected heart tissue. Consequently, immunofluorescence was used to detect NFAT2 and FOXO4 expression in heart tissue sections from CAWS-injected mice. NFAT2 expression

increased and FOXO4 decreased in the inflamed region of the heart tissue at 14 and 28 days after CAWS injection (Figures 5K, L and Supplementary Figure 2F–H). CDH5 expression decreased in the inflamed area, which was verified by western blotting (Figures 5M–O). Taken together, these data demonstrated that NFAT2 was upregulated and FOXO4 was downregulated in CAWS-induced heart tissues, especially in the inflamed region.

For better understand the phenotypic changes in inflamed region, we also performed immunofluorescence to detect classic immune cell infiltration. The results showed that macrophages (F4/80) and monocytes (CD14) infiltrated in the areas of high inflammation, which has been verified infiltrated in a KD-like mouse model abdominal aorta using single cell RNA-Seq (25) (Supplement Figure 3 A–D).

3.6 NFAT2 pharmacological blockade alleviates CAWS-induced KD vasculitis

NFAT2 expression increased in the inflammatory regions and the Ca²⁺/NFAT pathway plays an important role in KD (3); therefore, we used an NFAT2 inhibitor to determine whether it could inhibit inflammation in CAWS-induced KD vasculitis. The peptide 11R-VIVIT was used because it is a highly specific inhibitor of the NFAT signaling pathway. To observe the effect of 11R-VIVIT on the NFAT family, we detect the mRNA level of NFAT members in CAWS and 11R-VIVIT injected heart tissue. The results demonstrated the expression of *Nfat2* was downregulated most significantly among NFAT family members (Figure 6A). Compared with that in the CAWS +DMSO-injected control group, the NFAT2 protein level was significantly downregulated after 5 days of continuous 11R-VIVIT injection (Figures 6B, C).

To ascertain whether blocking NFAT2 directly would reduce CAWS-induced KD vasculitis, mice were administered with 11R-VIVIT for 5 consecutive days starting 1 h before CAWS injection. We found that 11R-VIVIT treatment significantly reduced CAWS-induced vasculitis (Figures 6D–F). NFAT2 expression also decreased in the inflamed region of the heart tissue at 14 days after 11E-VIVIT injection (Figures 6G, J). Treatment with 11R-VIVIT also increased CDH5 expression in the inflamed region of CAWS-injected heart tissue (Figures 6H–J). Taken together, our results showed that inhibition of NFAT2 using 11R-VIVIT partly prevented the development of CAWS-induced heart inflammation in mice.

3.7 NFAT2 acts as the downstream molecule of FOXO4 in CAWS-induced vasculitis

To determine FOXO4's *in vivo* functions, we bought the *Foxo4*-KO mouse from Cyagen Biosciences (designated as *Foxo4*^{em1cyagen}). The *Foxo4* gene (NM_018789) is located on mouse chromosome X and comprises three exons. To produce the KO mouse, all three exons were targeted by Cas9/gRNA co-injection into fertilized eggs (Figure 7A). Loss of *Foxo4* in the *Foxo4*-KO mice was verified by DNA electrophoresis (Supplementary Figure 4A). Wild-type (WT) mice and *Foxo4*^{em1cyagen} mice were injected with PBS or CAWS, respectively. After 14 days of injection, heart tissue was processed for HE and EVG-staining for histological examination (Supplementary Figure 4B). Compared with that in the WT group, the *Foxo4*^{em1cyagen} group showed increased heart artery inflammation after CAWS-induced KD vasculitis. There were no significant differences after PBS injection in both the WT and *Foxo4*^{em1cyagen} groups (Figures 7B–D). NFAT2 expression increased in the CAWS-injected *Foxo4*^{em1cyagen} group compared with that in the PBS-injected *Foxo4*^{em1cyagen} group and the CAWS-injected WT group (Figures 7E, H, Supplementary Figure 4C). In contrast, CDH5 expression decreased significantly in the CAWS-injected *Foxo4*^{em1cyagen} group compared with that in PBS injection group (Figures 7F–H).

These results encouraged us to assess whether FOXO4 modulates CAWS-induced vasculitis through NFAT2. We carried out rescue experiments in the *Foxo4*^{em1cyagen} group by simultaneously injecting CAWS and inhibiting NFAT2 using 11R-VIVIT (Supplementary Figure 4D). We observed that injection of 11R-VIVIT in the CAWS-injected *Foxo4*^{em1cyagen} group partly alleviated heart artery inflammation and the heart vessel inflammation scores also decreased (Figures 7I–K). Furthermore, 11R-VIVIT partially increased the expression of CDH5 and decreased the expression of NFAT2 in the inflamed region of CAWS-induced heart tissue (Figures 7L–O, Supplementary Figure 4E). As a result, we concluded that knockout of *Foxo4* promotes inflammation in CAWS-induced KD vasculitis, at least in part, by activating the transcription of *Nfat2*.

4 Discussion

Initially, this study was prompted by the observation that transcription factor (TF) NFAT2 is upregulated in immune cells and stromal cells through NFAT signaling, a pathway associated with KD. Recent studies on KD showed that the formation of vasculitis is highly related to the infiltration of immune cells into stromal cells (25). To better understand the role of the NFAT




FIGURE 6

11R-VIVIT alleviated CAWS-induced KD vasculitis. (A) qRT-PCR results for NFAT family members in CAWS+11R-VIVIT injected heart tissue ($n = 3$). (B, C) Immunoblotting analysis of NFAT2 levels in mouse heart tissues from CAWS groups and mouse models injected with an increasing amount of 11R-VIVIT. The loading control comprised β -Actin (B). NFAT2 levels in different groups quantified using ImageJ (C). (D-F) Different groups the mouse were sacrificed and heart tissues were harvested, made into sections, and then subjected to hematoxylin and eosin (HE) staining (D) and elastic van Gieson (EVG) staining (F). Heart vessel inflammation scores of WT mice in different groups was analyzed (F) ($n = 4$). (G) Immunofluorescent staining for NFAT2 (red) in heart sections from CAWS+DMSO/CAWS+11R-injected WT mice. All images show DAPI staining of nuclei. (H) immunohistochemical staining for CDH5 in heart sections from different groups. (I) CDH5 protein levels quantified by the H-score ($n = 4$). (J) Western blotting assessment of NFAT2 and CDH5 levels in different groups. The loading control comprised β -Actin. Scale bars, 200 μ m (50 \times) and 10 μ m (200 \times). Data are presented as the mean \pm SEM. Quantitative data were analyzed using Kruskal–Wallis tests (F) and one-way ANOVA (I), * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, **** $P < 0.0001$.

signaling pathway, especially that of NFAT2, in KD progression, we conducted our research from three different aspects. First, we identified that NFAT2 has the strongest transcriptional activation among NFAT family member. Second, we used TNF α -stimulated HCAECs to simulate the infiltration of stromal cells in vasculitis. Third, we used a CAWS-induced mouse model of KD vasculitis to study the overall changes in heart tissue, including both immune cells and stromal cells. In this study, we identified a novel pathway comprising FOXO4/NFAT2. This pathway affects endothelial cell homeostasis *in*

vitro and formation of CAWS-induced vasculitis *in vivo*. Our results showed that the downregulation of FOXO4 promoted NFAT2 expression, causing an imbalance in endothelial cell homeostasis and worsening of vascular inflammatory infiltration. Inhibition of *Nfat2* in *Foxo4*-KO mice reduced the level of inflammatory infiltration.

We found the NFAT2 expression was significantly elevated in immune cells (PBMCs) from patients with KD, similar to a previous study (26). Previous research also reported that NFAT inhibitors, such as cyclosporine, can prevent progression of




FIGURE 7

FOXO4-KO mice could exacerbate the vasculitis induced by CAWS, but the inflammation was relieved after blocking NFAT2. (A) The Cas9/gRNA method generated the FOXO4-KO mice. (B–D) Different groups of mice were sacrificed and heart tissues were harvested, made into section sections, and subjected to hematoxylin and eosin (HE)-staining (B) and elastic van Gieson (EVG) staining (C). Heart vessel inflammation scores of FOXO4-KO and WT mice in different groups were analyzed (D) ($n = 5$). (E) Immunofluorescence staining for FOXO4 (green) and NFAT2 (red) in heart sections of the PBS/CAWS-injected FOXO4-KO group mice. All images show DAPI staining of nuclei. (F) Immunohistochemical staining for CDH5 in heart sections from four different groups. (G) The CDH5 protein level quantified by the H-score ($n = 5$). (H) Western blotting determination of NFAT2, FOXO4, and CDH5 protein levels in different groups. The loading control comprised β -Actin. Different groups of FOXO4-KO mouse were sacrificed, and heart tissues were harvested and made into sections, which were subjected to HE staining (I) and EVG staining (J) sections. (K) Heart vessel inflammation scores of FOXO4-KO+CAWS, and FOXO4-KO+CAWS+11R mice were analyzed ($n = 5$). (L) Immunohistochemical staining for CDH5 in heart sections from different FOXO4-KO groups. (M) CDH5 protein levels quantified by the H-score ($n = 5$). (N) Immunofluorescence staining for FOXO4 (green) and NFAT2 (red) in heart sections from FOXO4-KO+CAWS+11R-injected group mice. All images show DAPI staining of nuclei. (O) Western blotting analysis of NFAT2 and CDH5 levels in different FOXO4-KO mouse groups. The loading control comprised β -Actin. Scale bars, 200 μ m (50x) and 10 μ m (200x). Data are presented as the mean \pm SEM. Quantitative data were analyzed using unpaired t tests (two-tailed) (D, K) and one-way ANOVA (E, M), * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, **** $P < 0.0001$.

inflammation in the arterial wall by blocking cytotoxic CD8+T cells infiltration into the arterial wall (27). This might represent the important impact of NFAT inhibitors KD patients' PBMCs. This could be explained by the fact that the Ca⁺/NFAT signaling pathway is activated in the acute stage of KD, and NFAT2 is an important TF in this pathway. In addition, NFAT2 was upregulated in PBMCs from CAWS-induced mice. To date, there has been no report about CAWS directly activating the NFAT signaling pathway; however, higher production of proinflammatory cytokines, including TNF α and interleukin (IL)-1 β , has been observed in the serum of CAWS-injected mice (28, 29). This might be the reasons why the NFAT pathway is activated and NFAT2 is upregulated.

As important stromal cells in heart tissue, HCAECs also have an important relationship with intravascular thrombosis (30), which is considered one of the most serious complications of KD (3). We selected HCAECs to study the mechanism of KD from the perspective of stromal cells. TNF α plays an importance role in KD, and was significantly elevated in patients' plasma; therefore, anti-TNF- α therapy has been a common treatment option for patients with intravenous immunoglobulin (IVIG) resistant KD (31–33). Consequently, we used TNF α to stimulate HCAECs to simulate the effect of inflammatory factors on stromal cells *in vitro*. Similar to previous research, NFAT2 expression increased significantly after TNF α stimulation (4). To better understand the changes in NFAT2 expression *in vivo*, we observed the expression of NFAT2 in heart tissue, especially in the inflamed areas, after CAWS-induced vasculitis. Those observations were similar to those made in previous research, in which stimulation by proinflammatory cytokines, such as TNF α , upregulated NFAT2 in both PBMCs and endothelial cells (4, 34). We also found that inhibiting NFAT2 expression using 11R-VIVIT could alleviate vascular inflammation. 11R-VIVIT is not a specific inhibitor of NFAT2. However, no specific inhibitor of NFAT2 is currently available. NFAT2 shows the strongest transcriptional activity, thus most 11R-VIVIT studies have focused on NFAT2 rather than other members of NFAT family, as did our design (35, 36). 11R-VIVIT selectively interferes with the calcineurin-NFAT2 interaction without altering the calcineurin phosphatase activity *in vivo* and *in vitro* (37–39).

We also found that an increase of NFAT2 in endothelial cells decreased the function of intercellular junctions *via* CDH5. *In vitro*, similar to previous experiments using human umbilical vein endothelial cells, CDH5 expression decreased significantly after being stimulated by proinflammatory factors (40). *In vivo*, cardiac ischemic injury, cardiac fibrosis, and even occlusion formation were also observed in *Cdh5*-KO mice (40, 41). These changes are similar to the cardiovascular manifestations of KD. Moreover, in acute KD, dysregulation of endothelial cell homeostasis probably affects aneurysm formation and vascular wall injury (4). These might be one of reasons why suppressing

the Ca⁺/NFAT signaling pathway can reduce coronary artery lesions in KD.

Mammals have four FOXO TFs: FOXO1, FOXO3a, FOXO4, and FOXO6 (42). FOXO4 is mainly involved in cell cycle arrest, apoptosis, and muscle homeostasis (43). To date, there has been no research on the role or mechanism of FOXO4 in KD. However, previous studies provided several possibilities: 1) Inflammatory cytokine expression. A previous study reported that FOXO4 represses the expression of inflammatory cytokines, such as TNF α and IL-1 β , which have vital functions in the mechanism of KD (44). 2) Preventing aortic aneurysm formation. Blocking the nuclear translocation of FOXO4 stimulated aortic aneurysm formation (45). Coronary or aortic aneurysms are important complications of KD; therefore, FOXO4 might have a protective role in the progress of KD.

At day 28 after CAWS injection, we found the mRNA and protein levels of FOXO4 were upregulated, for which there are two possible reasons. Firstly, it might suggest that the heart tissue is entering the subacute phase/recovery phase. Acute arteritis mainly involves immune cell infiltration, and subacute chronic arteritis in KD involves luminal myofibroblast proliferation (24). In our mouse model, at day 14, arteries are mainly infiltrated by immune cells, and their shape is normal. However, at day 28, luminal myofibroblasts obviously proliferate and vessels lose their original shape (Figure 5D), which indicated that vasculitis has entered the subacute phase. We found that FOXO4 might be a protector in the process of KD-like vasculitis, such that the level of FOXO4 could increase in the subacute or recovery phase. Secondly, FOXO4 might be uncoupled from NFAT2 when the disease enters the subacute phase; but the mechanism of this phenotype needs to be further studied in the future. At day 28, the CAWS mice tended to regain the weight lost by day 14, perhaps for the same reason. When the mice entered into the subacute phase, their weight recovered gradually.

Interestingly, *in vivo*, the level of inflammation in CAWS-injected heart tissue in the *Foxo4*-KO group was more serious than that in the WT group. Previous studies using *Foxo4*-KO mice reported that the *Foxo4*-KO group produced more severe inflammatory infiltration (44, 46). *Foxo4*-KO immune cells would increase resident smooth muscle cell proliferation and endothelial cell dysfunction, which would further enhance inflammation and the formation of coronary/aorta vasculitis (46). Consistently, we demonstrated that the NFAT inhibitor, 11R-VIVIT, attenuated CAWS-induced inflammatory responses in *Foxo4*-KO heart tissue. This indicated that the FOXO4/NFAT2 signaling pathway functions not only in HCAECs, but also in mouse heart tissue.

There are several limitations of this study. First, we only examined PBMCs from patients with KD and health controls, and further study should focus on patients with KD with and without coronary artery lesions. Second, the mechanism by which FOXO4 is downregulated in different cells or tissues remains unknown. Third, although we demonstrated that

FOXO4 inhibits *NFAT2* transcription by physically binding to a region of its promoter, the exact mechanism of this inhibition remains to be determined. For example, does FOXO4 represses *NFAT2* transcription by competitive inhibition of its activator and why does FOXO4 appear to be uncoupled from *Nfat2* when the mice entered the subacute phase. Fourth, 11R-VIVIT might affect other NFAT family members; therefore, we need a specific inhibitor of NFAT2 to improve our experiments in the future. These aspects will be examined in future studies.

In this study, NFAT2 was identified to have an important role in the Ca²⁺/NFAT pathway. Moreover, partly through its negative regulation of NFAT2, FOXO4 functions as a transcriptional repressor to suppress vasculitis and maintain endothelial cell homeostasis, thereby controlling vasculitis in KD. The FOXO4/NFAT2 signaling pathway could be developed as a novel therapeutic target, and exploiting its related intrinsic inhibitory mechanisms could lead to novel therapies to prevent and treat KD.

Q15 Data availability statement

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/[Supplementary material](#).

Q16 Ethics statement

The studies involving human participants were reviewed and approved by the Ethics Committee of Soochow University Affiliated Children's Hospital (approval no. 2020CS075). Written informed consent to participate in this study was provided by the participants' legal guardian/next of kin. The animal study was reviewed and approved by Animal Care and Use Committee of Soochow University.

Q18 Author contributions

HH conceived and coordinated the project, analyzed the data, and wrote the paper. HH, JD, and JJ performed the majority of the experiments. YZ performed the qRT-PCR experiments. JD and SW carried out the transfection of lentivirus targeting FOXO4 and NFAT2 experiments. JD and JJ supported the ChIP-qPCR experiments. HH, JJ, YZ, and NW performed the animal experiments. YD, JM and MH help with the *in vivo* experiments. WZ, FY, LM, DY, GY, and QC provided critical ideas and comments for the NFAT2 and FOXO4 study,

HL, HH, JD, DY, WQ and GQ discussed the results. HL and LG critically discussed the data and read and revised the manuscript. All authors contributed to the article and approved the submitted version.

Funding

Q13

This work was supported by the National Natural Science Foundation of China [grant numbers 81870365, 81970436, 82270512, and 82070529] and the Project of Education and Scientific Research for Young and Middle aged Teachers in Fujian Province, China [grant number JAT200124].

Acknowledgments

Q19

The authors are grateful to the Institute of Pediatric Research, Children's Hospital of Soochow University, for their provision of the equipment necessary to carry out the study. HH received support from the China Scholarship Council for 1 year study at the Max-Planck Institute for Heart and Lung Research. LG was supported by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation), EXC 2026, Cardio-Pulmonary Institute (CPI), Project ID 390649896.

Conflict of interest

Q14

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

Q17

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fimmu.2022.1090056/full#supplementary-material>

References

1. Huang H, Xu L, Ding Y, Qin J, Huang C, Li X, et al. Bioinformatics identification of hub genes and signaling pathways regulated by intravenous immunoglobulin treatment in acute Kawasaki disease. *Exp Ther Med* (2021) 22(1):784. doi: 10.3892/etm.2021.10216
2. Fukazawa R, Kobayashi J, Ayusawa M, Hamada H, Miura M, Mitani Y, et al. Jcs/Jscs 2020 guideline on diagnosis and management of cardiovascular sequelae in Kawasaki disease. *Circ J* (2020) 84(8):1348–407. doi: 10.1253/circj.CJ-19-1094
3. McCrindle BW, Rowley AH, Newburger JW, Burns JC, Bolger AF, Gewitz M, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: A scientific statement for health professionals from the American heart association. *Circulation* (2017) 135(17):e927–e99. doi: 10.1161/CIR.0000000000000484
4. Wang Y, Hu J, Liu J, Geng Z, Tao Y, Zheng F, et al. The role of Ca(2+)/Nfat in dysfunction and inflammation of human coronary endothelial cells induced by sera from patients with Kawasaki disease. *Sci Rep* (2020) 10(1):4706. doi: 10.1038/s41598-020-61667-y
5. Onouchi Y, Gunji T, Burns JC, Shimizu C, Newburger JW, Yashiro M, et al. Itpkc functional polymorphism associated with Kawasaki disease susceptibility and formation of coronary artery aneurysms. *Nat Genet* (2008) 40(1):35–42. doi: 10.1038/ng.2007.59
6. Serfling E, Barthelmäs R, Pfeuffer I, Schenk B, Zarius S, Swoboda R, et al. Ubiquitous and lymphocyte-specific factors are involved in the induction of the mouse interleukin 2 gene in T lymphocytes. *EMBO J* (1989) 8(2):465–73. doi: 10.1002/j.1460-2075.1989.tb03399.x
7. McCaffrey PG, Luo C, Kerppola TK, Jain J, Badalian TM, Ho AM, et al. Isolation of the cyclosporin-sensitive T cell transcription factor nfatp. *Science* (1993) 262(5134):750–4. doi: 10.1126/science.8235597
8. Northrop JP, Ho SN, Chen L, Thomas DJ, Timmerman LA, Nolan GP, et al. Nfat components define a family of transcription factors targeted in T-cell activation. *Nature* (1994) 369(6480):497–502. doi: 10.1038/369497a0
9. Vaeth M, Feske S. Nfat control of immune function: New frontiers for an abiding trooper. *Front Immunol* (2018) 9:13426. doi: 10.3389/fimmu.2018.013426
10. Aramburu J, Yaffe MB, López-Rodríguez C, Cantley LC, Hogan PG, Rao A. Affinity-driven peptide selection of an nfat inhibitor more selective than cyclosporin a. *Science* (1999) 285(5436):2129–33. doi: 10.1126/science.285.5436.2129
11. Stock AT, Hansen JA, Sleeman MA, McKenzie BS, Wicks IP. Gm-csf primes cardiac inflammation in a mouse model of Kawasaki disease—csf triggers cardiac inflammation. *J Exp Med* (2016) 213(10):1983–98. doi: 10.1084/jem.20151853
12. Zhang Q, Duan J, Yang B, Yu D, Liu L, Bai H. Cathepsin b regulates the activation of Nlrp3 inflammasome by calcium signaling. (2018).
13. Jia C, Zhang J, Chen H, Zhuge Y, Chen H, Qian F, et al. Endothelial cell pyroptosis plays an important role in Kawasaki disease Via Hmgb1/Rage/Cathepsin b signaling pathway and Nlrp3 inflammasome activation. *Cell Death Dis* (2019) 10(10):778. doi: 10.1038/s41419-019-2021-3
14. Hamaoka-Okamoto A, Suzuki C, Yahata T, Ikeda K, Nagi-Miura N, Ohno N, et al. The involvement of the vasa vasorum in the development of vasculitis in animal model of Kawasaki disease. *Pediatr Rheumatol* (2014) 12(1):1–9. doi: 10.1186/1546-0096-12-12
15. Lee Y, Schulte DJ, Shimada K, Chen S, Crother TR, Chiba N, et al. Interleukin-1beta is crucial for the induction of coronary artery inflammation in a mouse model of Kawasaki disease. *Circulation* (2012) 125(12):1542–50. doi: 10.1161/CIRCULATIONAHA.111.072769
16. Paschalis A, Sheehan B, Riisnaes R, Rodrigues DN, Gurel B, Bertain C, et al. Prostate-specific membrane antigen heterogeneity and DNA repair defects in prostate cancer. *Eur Urol* (2019) 76(4):469–78. doi: 10.1016/j.eururo.2019.06.030
17. La Madrid AM, Campbell N, Smith S, Cohn SL, Salgia R. Targeting alk: A promising strategy for the treatment of non-small cell lung cancer, non-hodgkin's lymphoma, and neuroblastoma. *Targ Oncol* (2012) 7(3):199–210. doi: 10.1007/s11523-012-0227-8
18. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative pcr and the 2⁻ΔΔct method. *methods* (2001) 25(4):402–8. doi: 10.1006/meth.2001.1262
19. Chen Y-L, Li X-L, Li G, Tao Y-F, Zhuo R, Cao H-B, et al. Brd4 inhibitor Gne987 exerts anti-cancer effects by targeting super-enhancers in neuroblastoma. *Cell Biosci* (2022) 12(1):1–20. doi: 10.1186/s13578-022-00769-8
20. Skaria T, Bachli E, Schoedon G. Wif1 prevents Wnt5a mediated Limk/Cfl phosphorylation and adherens junction disruption in human vascular endothelial cells. *J Inflammation (Lond)* (2017) 14:10. doi: 10.1186/s12950-017-0157-4
21. Bai S, Wei Y, Hou W, Yao Y, Zhu J, Hu X, et al. Orai-Igfbp3 signaling complex regulates high-glucose exposure-induced increased proliferation, permeability, and migration of human coronary artery endothelial cells. *BMJ Open Diabetes Res Care* (2020) 8(1). doi: 10.1136/bmjdr-2020-001400
22. Lee C, Huang C-H. Lasagna-search 2.0: Integrated transcription factor binding site search and visualization in a browser. *Bioinformatics* (2014) 30(13):1923–5. doi: 10.1093/bioinformatics/btu1923
23. Fang J, Ji Y-X, Zhang P, Cheng L, Chen Y, Chen J, et al. Hepatic Irf2bp2 mitigates nonalcoholic fatty liver disease by directly repressing the transcription of Atf3. *Hepatology* (2020) 71(5):1592–608. doi: 10.1002/hep.30950
24. Noval Rivas M, Arditi M. Kawasaki Disease: Pathophysiology and insights from mouse models. *Nat Rev Rheumatol* (2020) 16(7):391–405. doi: 10.1038/s41584-020-0426-0
25. Porritt RA, Zemmour D, Abe M, Lee Y, Narayanan M, Carvalho TT, et al. Nlrp3 inflammasome mediates immune-stromal interactions in vasculitis. *Circ Res* (2021) 129(9):e183–200. doi: 10.1161/CIRCRESAHA.121.319153
26. Lv YW, Chen Y, Lv HT, Li X, Tang YJ, Qian WG, et al. Kawasaki Disease Ox40-Ox40l axis acts as an upstream regulator of nfat signaling pathway. *Pediatr Res* (2019) 85(6):835–40. doi: 10.1038/s41390-019-0312-0
27. Burns JC. Cyclosporine and coronary outcomes in Kawasaki disease. *J Pediatr* (2019) 210:239–42. doi: 10.1016/j.jpeds.2019.04.044
28. Nakamura J, Watanabe S, Kimura H, Kobayashi M, Karasawa T, Kamata R, et al. Adeno-associated virus vector-mediated interleukin-10 induction prevents vascular inflammation in a murine model of Kawasaki disease. *Sci Rep* (2018) 8(1):7601. doi: 10.1038/s41598-018-25856-0
29. Zhang J, Zhuge Y, Rong X, Ni C, Niu C, Wen Z, et al. Protective roles of xijiao dihuang tang on coronary artery injury in Kawasaki disease. *Cardiovasc Drugs Ther* (2021). doi: 10.1007/s10557-021-07277-w
30. Chin-Quee SL, Hsu SH, Nguyen-Ehrenreich KL, Tai JT, Abraham GM, Pacetti SD, et al. Endothelial cell recovery, acute thrombogenicity, and monocyte adhesion and activation on fluorinated copolymer and phosphorylcholine polymer stent coatings. *Biomaterials* (2010) 31(4):648–57. doi: 10.1016/j.biomaterials.2009.09.079
31. Burns JC, Mason WH, Hauger SB, Janai H, Bastian JF, Wohrley JD, et al. Infliximab treatment for refractory Kawasaki syndrome. *J Pediatr* (2005) 146(5):662–7. doi: 10.1016/j.jpeds.2004.12.022
32. Shimizu M, Mizuta M, Usami M, Inoue N, Sakakibara Y, Yamada K, et al. Clinical significance of serum soluble tnfr receptor ii level and soluble tnfr receptor Ii/I ratio as indicators of coronary artery lesion development in Kawasaki disease. *Cytokine* (2018) 108:168–72. doi: 10.1016/j.cyto.2018.03.037
33. Yamaji N, da Silva Lopes K, Shoda T, Ishitsuka K, Kobayashi T, Ota E, et al. Tnf-alpha blockers for the treatment of Kawasaki disease in children. *Cochrane Database Syst Rev* (2019) 8:CD012448. doi: 10.1002/14651858.CD012448.pub2
34. Yokota K, Sato K, Miyazaki T, Aizaki Y, Tanaka S, Sekikawa M, et al. Characterization and function of tumor necrosis factor and Interleukin-6-induced osteoclasts in rheumatoid arthritis. *Arthritis Rheumatol* (2021) 73(7):1145–54. doi: 10.1002/art.41666
35. Xie Z-Y, Dong W, Zhang L, Wang M-J, Xiao Z-M, Zhang Y-H, et al. Nfat inhibitor 11r-vivit ameliorates mouse renal fibrosis after ischemia-Reperfusion-Induced acute kidney injury. *Acta Pharmacol Sin* (2022) 43(8):2081–93. doi: 10.1038/s41401-021-00833-y
36. Liu F, Zhu Z, Mao Y, Liu M, Tang T, Qiu S. Inhibition of titanium particle-induced osteoclastogenesis through inactivation of Nfatc1 by vivit peptide. *Biomaterials* (2009) 30(9):1756–62. doi: 10.1016/j.biomaterials.2008.12.018
37. Dou C, Zhang H, Ke G, Zhang L, Lian Z, Chen X, et al. The kruppel-like factor 15-Nfatc1 axis ameliorates podocyte injury: A novel rationale for using glucocorticoids in proteinuria diseases. *Clin Sci (Lond)* (2020) 134(12):1305–18. doi: 10.1042/CS20200075
38. Noguchi H, Sugimoto K, Miyagi-Shiohira C, Nakashima Y, Kobayashi N, Saitoh I, et al. Rcan-11r peptide provides immunosuppression for fully mismatched islet allografts in mice. *Sci Rep* (2017) 7(1):3043. doi: 10.1038/s41598-017-02934-3
39. Zhang L, Li R, Shi W, Liang X, Liu S, Ye Z, et al. Nfat2 inhibitor ameliorates diabetic nephropathy and podocyte injury in Db/Db mice. *Br J Pharmacol* (2013) 170(2):426–39. doi: 10.1111/bph.12292
40. Jordan NP, Tingle SJ, Shuttleworth VG, Cooke K, Redgrave RE, Singh E, et al. Mir-126-3p is dynamically regulated in endothelial-to-Mesenchymal transition during fibrosis. *Int J Mol Sci* (2021) 22(16). doi: 10.3390/ijms22168629
41. Patel J, Baz B, Wong HY, Lee JS, Khosrotehrani K. Accelerated endothelial to mesenchymal transition increased fibrosis Via deleting notch signaling in wound vasculature. *J Invest Dermatol* (2018) 138(5):1166–75. doi: 10.1016/j.jid.2017.12.004
42. Link W. Introduction to foxo biology. *FOXO transcription factors*. (2019), 1–9. doi: 10.1007/978-1-4939-8900-3_1

43. Liu W, Li Y, Luo B. Current perspective on the regulation of Foxo4 and its role in disease progression. *Cell Mol Life Sci* (2020) 77(4):651–63. doi: 10.1007/s00018-019-03297-w

44. Zhou W, Cao Q, Peng Y, Zhang QJ, Castrillon DH, DePinho RA, et al. Foxo4 inhibits nf-kappab and protects mice against colonic injury and inflammation. *Gastroenterology* (2009) 137(4):1403–14. doi: 10.1053/j.gastro.2009.06.049

45. Zhao G, Fu Y, Cai Z, Yu F, Gong Z, Dai R, et al. Unspliced Xbp1 confers vsmc homeostasis and prevents aortic aneurysm formation Via Foxo4 interaction. *Circ Res* (2017) 121(12):1331–45. doi: 10.1161/CIRCRESAHA.117.311450

46. Zhu M, Zhang QJ, Wang L, Li H, Liu ZP. Foxo4 inhibits atherosclerosis through its function in bone marrow derived cells. *Atherosclerosis* (2011) 219(2):492–8. doi: 10.1016/j.atherosclerosis.2011.09.038